Mark N. Gaze

Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial

Ruth Ladenstein, Ulrike Pötschger, Dominique Valteau‐Couanet et al. · The Lancet Oncology · 2018 · 379 citations

Interleukin 2, Autoimmune Disease, Anti-gd2 Antibody Ch14.18/cho +7

Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial

Ruth Ladenstein, Ulrike Pötschger, Andrew D.J. Pearson et al. · The Lancet Oncology · 2017 · 334 citations · Full text

Oncology, Medicine, Versus Carboplatin +8

Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial

Gianni Bisogno, Meriel Jenney, Christophe Bergeron et al. · The Lancet Oncology · 2018 · 182 citations

Oncology, Medicine, Dose-intensified Doxorubicin +10

¹⁷⁷Lu-DOTATATE Molecular Radiotherapy for Childhood Neuroblastoma

J. Gains, Jamshed Bomanji, Naomi Fersht et al. · Journal of Nuclear Medicine · 2011 · 160 citations · Full text

Feasibility of Dosimetry-Based High-Dose ¹³¹ I-Meta-Iodobenzylguanidine with Topotecan as a Radiosensitizer in Children with Metastatic Neuroblastoma

Mark N. Gaze, Yen-Ching Chang, Glenn Flux et al. · Cancer Biotherapy and Radiopharmaceuticals · 2005 · 141 citations